Epidermal growth factor receptor (EGFR) is overexpressed or mutated in a high percentage of tumors. EGFR has long been considered a promising target for cancer diagnostic and therapeutic applications. However, monoclonal antibodies and other large antibody constructs diffuse into tumors slowly, limiting their efficacy. To develop lower molecular weight probes for EGFR and other tumor cell receptors, the authors immunized a llama with the extracellular domains (ECDs) of EGFR and an oncogenic mutant receptor, EGFRvIII, and with extracts of tumor cell lines. From the immune repertoire of the llama, the authors constructed a heavy chain variable domain (VHH domain)-phage library. At~16 kDa, the VHH domain is a tenth of the size of a monoclonal antibody and is the smallest antibody fragment that retains specificity. By affinity selection from this library, the authors isolated many VHH domains with specificity for EGFR. The VHH domains bind to whole cells expressing the receptor but not to control cells lacking the receptor and can immunoprecipitate EGFR from cell lysates. Some VHH domains have cross-specificity with existing anti-EGFR monoclonal antibodies and have reasonably high (nM) affinities. The llama-VHH domain library is also potentially a rich source of targeting agents directed toward other tumor cell receptors. (Journal of Biomolecular Screening 2009:77-85) 
INTRODUCTION
M UCH EFFORT HAS BEEN EXERTED ON SEARCHES for tumor-specific targeting agents for either diagnostic or therapeutic purposes. One approach has been to focus on cell membrane receptors that are either uniquely expressed or significantly overexpressed in tumor cells. Epidermal growth factor receptor (EGFR) is a well-studied representative of this type of cancer marker. EGFR (or ErbB-1) is a member of a family of transmembrane tyrosine kinase receptors whose other members are HER2/c-neu (ErbB-2), Her3 (ErbB-3), and Her4 (ErbB-4). EGFR is a 170-kDa protein with an extracellular ligand-binding domain, a membrane-spanning region, and an intracellular tyrosine kinase domain. 1 Upon ligand binding, the receptor forms a homodimer or heterodimer with another member of the receptor family. 2 Ligand binding leads to activation of receptor tyrosine kinase activity, which triggers downstream growth-promoting signaling pathways. 3 EGFR is then downregulated by endocytic internalization, compartmentalization, and degradation. 4 Although EGFR is present on the surface of most normal cells, overexpression of wild-type EGFR and expression of mutated EGFR have been associated with tumors of the lung, brain, breast, ovary, prostate, and other cancers. [5] [6] [7] [8] [9] [10] EGFR amplification has been found to be strongly correlated with tumor progression. [11] [12] [13] Activating mutations of EGFR can be found in both the extracellular domain (ECD) and intracellular kinase domain. The EGFRvIII mutation is present in a significant fraction of non-small cell lung cancers, breast carcinomas, and glioblastomas. [14] [15] [16] EGFRvIII is characterized by a 267-amino acid deletion that creates a unique epitope in the ECD. 17 This mutation renders the receptor ligand independent, constitutively active, and oncogenic. Other oncogenic mutations that occur in the intracellular domain have altered signaling properties. 18 Monoclonal antibodies (mAbs) with specificity for the ECD of EGFR have been developed into therapeutic agents. The anti-EGFR mAbs cetuximab and panitumumab are used for treatment of EGFR-positive colorectal cancer, 19, 20 and trastuzumab is used for treatment of HER2/c-neu (ErbB-2) positive breast cancer. 21 However useful mAbs may be, they are not optimal therapeutic or imaging reagents because of the slow tumor penetration of a 160-kDa protein. The naturally occurring heavy chain antibodies of camels and llamas may provide a source of low molecular weight yet specific tumor-targeting agents. 22 These antibodies are devoid of light chains; the antigen-binding domain is composed solely of the variable regions of 2 heavy chains. A 16-kDa monomeric protein derived from a single heavy chain variable region, termed the VHH domain, is the smallest antigen-binding fragment known. 23 These molecules are highly soluble when expressed in a recombinant system, do not aggregate as do some scFvs, and are nonimmunogenic in mice. 24, 25 A VHH domain has been shown to cross the bloodbrain barrier. 26 It was recently reported that a phase I clinical trial of a VHH domain targeting von Willebrand factor in humans showed the VHH domain to cause no adverse effects (http://www.ablynx.com).
We have constructed a llama-VHH domain library and show here that large numbers of EGFR-specific VHH domains can be isolated from it with ease. This llama-VHH domain library is also potentially a source of targeting agents directed toward other tumor cell receptors. The isolation of several EGFR-specific VHH domains has been reported previously by Roovers et al. 27 Although that study focused on the biological activity of monovalent and multivalent VHH domains, the current study is a detailed account of the screening method for isolating EGFR-specific VHH domains and their biochemical characterization.
MATERIALS AND METHODS
The EGFR mAb, H11, was purchased from Dako (Carpinteria, CA). All other EGFR-specific mAbs were a gift of Dr. D. Bigner, Duke University Medical Center (Durham, NC). Zinc Option medium, RPMI 1640 medium, and fetal bovine serum (FBS) were purchased from Gibco-Invitrogen (Carlsbad, CA). The 96-well coated microplates were from BD Biosciences (San Jose, CA).
Cell lines
The NR6M, NR6W, and NR6V cell lines are Swiss mouse 3T3 cells transfected with human EGFRvIII, human EGFR wild type, or vector, respectively. 28 These 3 cell lines and the human glioblastoma cell line U87MG 29 were obtained from Dr. D. Bigner. All were grown in Zinc Option + 10% FBS. The human adenocarcinoma cell line ADLC-5M2 30 was obtained from Dr. G. Bepler (H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL) and grown in RPMI 1640 + 10% FBS. All cell lines were maintained at 37°C in a 5% CO 2 incubator.
Llama immunization
Llama immunization and subsequent care were carried out under an animal protocol approved by our Institutional Animal Care and Use Committee (IACUC). ADLC-5M2 and U87MG cells were harvested with 5 mM EDTA in phosphate-buffered saline (PBS), and proteins were extracted by incubation for 30 min at 4°C with Mammalian Protein Extraction Reagent (M-PER; Pierce, Rockford, IL) containing protease inhibitors (Complete Protease Inhibitor Cocktail, Roche Applied Science, Indianapolis, IN). Cellular debris was removed by centrifugation at 16,000 g for 10 min at 4°C. The resultant lysate was stored at -80°C until use. For immunization, purified recombinant proteins (100 µg each EGFR-ECD and EGFRvIII ECD) and cell lysate proteins (50 µg U87MG and 80 µg ADLC-5M2) were added to adjuvant (Stimune, Cedi Diagnostics, Lelystad, The Netherlands) at a ratio of 4 parts protein solution to 5 parts adjuvant and mixed thoroughly to form an emulsion. The emulsion (total volume 2 mL) was then injected into a llama, half subcutaneously and half intramuscularly. The llama was boosted using the same protocol 25 days later, and blood was collected 39 days after the boost. Assay of the sera before and after the injections indicated a specific humoral response to EGFR.
Library construction
Peripheral blood lymphocytes were isolated using Lymphoprep (Axis-Shield, Oslo, Norway). RNA was purified from 4.5 × 10 7 lymphocytes using the Versagene Total RNA Purification kit (Gentra, Minneapolis, MN), and 5 µg RNA was converted to cDNA using Transcriptor reverse transcriptase (Roche Applied Science). The variable domain of the heavy chain-only llama IgG was amplified by PCR. The amplification strategy was based on that described previously. 31, 32 Two separate amplifications were performed using a common reverse primer (VhbackSfiI) and 1 of 2 different forward primers, 1 priming on the "short-hinge region" (SHNotI) and 1 priming on the "long-hinge region" (LHNotI) of this class of antibodies. The sequences of the primers were as follows:
The PCR products were agarose gel purified and combined, digested with SfiI and NotI, and ligated upstream of the bacteriophage fd gene III in SfiI/NotI-cut phagemid vector pHEN1 33 modified to contain a carboxyl terminal 6-His tag (gift of D. Drabek, Erasmus MC, Rotterdam, The Netherlands). This phagemid replicates as a plasmid in Escherichia coli; when the library is subsequently "rescued" in the presence of "helper" phage, the VHH-gene III protein fusion is incorporated into the progeny phage as part of the tail assembly. The ligation mixture (2 µg total DNA) was introduced 25 ng at a time into electrocompetent E. coli TG1 cells (Stratagene, La Jolla, CA) using a Micropulser electroporation apparatus (Bio-Rad, Hercules, CA). A total of approximately 1 × 10 7 transformants were recovered, and the library was amplified and rescued with helper phage VCSM13 using established methods. 34 
Purification of EGFR ECDs
High Five insect cells (Invitrogen, Carlsbad, CA) were infected with a viral stock containing either a EGFRvIII ECD or wild-type EGFR expression vector. After harvesting infected cells, culture supernatant was dialyzed against PBS (pH 7.4), passed through a 0.2-µm filter, and applied to an immunoaffinity column (Sepharose 4B conjugated to EGFR-specific mAb H11). The column was eluted with glycine HCl buffer (pH 3.0), and all fractions containing protein were combined and dialyzed against PBS.
Affinity selection
For each round of selection, 10 pmole of EGFR ECD (wild type or vIII mutant) in 0.1 M NaHCO 3 (pH 8.5) was bound to a well of a "high-binding" microplate (Greiner Bio-One, Stonehouse, UK) at 4°C overnight. The wells were blocked for 1 h with 1% BSA in the same buffer. The plate was washed with PBS plus 0.1% (v/v) Tween-20 (PBST), and 1 × 10 11 library phage were added to the wells. Phage were allowed to bind to the target for 3 h at room temperature, after which they were removed and the wells were washed 8 times with PBST. Phage were eluted from the target by alternating acid (50 mM glycine, pH 2.2) and base (100 mM triethylamine, pH 10) treatment, the solution was neutralized with Tris-HCl (pH 7.4), and E. coli TG1 was infected with the eluted phage for amplification. Following phagemid amplification, phage rescue was performed to generate the input phage for the next round of selection. Four rounds of selection were performed.
Cell enzyme-linked immunosorbent assay
NR6W, NR6M, and NR6V were plated at an initial density of 5 × 10 4 cells per well in 96-well poly-L-lysine, poly-Dlysine, or collagen-coated microplates in serum-containing media. The microplates were incubated for 16 h to allow surface attachment, and all cell lines became confluent in this time. Media were removed, and cells were washed with PBS and fixed by adding 100 µL 0.025% glutaraldehyde (Sigma, St. Louis, MO) to each well for 2 min. The glutaraldehyde was removed, and the cells were washed with PBS. For the enzymelinked immunosorbent assay (ELISA), the plates were washed 4 times with PBS + 0.1% Tween-20 (PBST), and then 100 µL phage supernatant was added to each well. The plates were incubated at room temperature for 1 h and washed 4 times with PBST. Anti-M13-HRP antibody conjugate (GE Healthcare, Waukesha, WI) was diluted 1:1000 in PBST, and 100 µL was added to each well. After a 1-h incubation, the plates were washed and developed with 1 mM 2, 2′-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) in 50 mM citrate plus 0.03% H 2 O 2 . The plates were read at 405 nm on a 96-well microplate reader (Tecan, Männedorf, Switzerland). For competition ELISA, antibodies were diluted in a microplate and then transferred to the cell ELISA plate in a volume of 25 µL. Phage (75 µL) were immediately added, the plates were incubated for 1 h, and they were processed as described above.
Immunoprecipitation
Free VHH domains were expressed in and purified from E. coli HB2151 periplasm by nickel affinity chromatography using His SpinTrap columns (GE Healthcare) according to the manufacturer's instructions. In HB2151, VHH domains are expressed as free soluble fragments due to a lack of amber suppression at the VHH-gene IIIp junction. The purified VHH domains were used to pull down target protein from mammalian cell lysates by 2 different methods.
For plate pull-down, 20 µg of each of 6 EGFR-specific VHH domains and 1 random VHH clone was placed in individual wells of a nickel-chelate microplate (Sigma His-Select HC; nominal capacity 4 µg); an eighth well received only buffer. The VHH domains were allowed to bind to the plate wells for 16 h at 4°C, and then the wells were washed 3 times with Trisbuffered saline containing 0.1% (v/v) Tween-20 (TBST). NR6W lysate (450 µg) made with M-Per reagent (Pierce) plus EDTA-free protease inhibitors (Roche Applied Science) was added to each well and allowed to incubate for 16 h at 4°C. The lysate was removed, and the wells were washed 15 times with TBST. Protein remaining on the well surface was eluted in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer containing 1% β-mercaptoethanol and 100 mM imidazole, preheated to 95°C. Samples were subjected to SDS-PAGE, and proteins were transferred to a polyvinylidene fluoride (PVDF) membrane that was then probed with the anti-EGFR mAb H11 and a secondary goatanti-mouse IgG-HRP conjugate. The blot was developed with SuperSignal West substrate (Pierce) and exposed to film.
For bead pull-down, VHH122 and negative control VHH RP2 were each coupled to CNBr-activated Sepharose 4B beads (GE Healthcare) according to the manufacturer's instructions and incubated with NR6W lysate for 3 h at 4°C. The beads were washed 5 times with PBS and protein eluted with SDS-Protein Sample Buffer at 95°C. Eluted protein was subjected to SDS-PAGE and stained with Coomassie Blue; a single band unique to the VHH122 lane was excised from the
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gel. This protein was subjected to tryptic digestion and sequence analysis by mass spectrometry at the UNC/Duke Proteomics Center (Chapel Hill, NC).
Surface plasmon resonance
The EGFR ECDs were coupled to Biacore CM5 chips, and VHH domains were flowed over each protein in HEPESbuffered saline solution in the Biacore 3000 at room temperature. Surface plasmon resonance measurements were taken, and the binding and dissociation phases were fit by the instrument's software to obtain rate and affinity constants.
Flow cytometry
NR6W and NR6V cells were grown to confluence, and cells were harvested with 0.02% EDTA in PBS. The cells were washed with PBS and resuspended in Zinc Option medium, with no serum. Cells (8 × 10 5 ) were mixed with either VHH122 or the random control RP2 at 15 µg/mL and incubated for 1 h on ice. The cells were washed 2 times each with 3 mL PBS and then resuspended in a solution of FITC-conjugated mouse anti-His tag mAb (Abcam ab53178) diluted 1:100 in Zinc Option medium. After incubation for 30 min on ice, the cells were washed and analyzed in a Becton Dickinson (Franklin Lakes, NJ) FACScalibur flow cytometer.
RESULTS

Affinity selection of EGFR-specific clones
A llama was immunized with a mixture of EGFR ECDs (wild type and vIII mutant) and cell lysates (lung adenocarcinoma and glioblastoma). Lymphocytes were isolated, and a llama-VHH domain phagemid library was constructed. The library contained approximately 10 7 recombinants, and sequencing of 20 random isolates revealed each to be unique and all to have the characteristic framework (FR) and complementaritydetermining regions (CDRs) of a llama heavy-chain variable domain. 35 Using this library, we performed 4 rounds of affinity selection by phage display on purified ECDs of EGFR and EGFRvIII. We observed that between rounds 1 and 3, the number of eluted phage (output) as a fraction of total phage added to the well (input) increased 1000-fold for both selections. However, there was no rise in output/input between rounds 3 and 4; therefore, the selection appeared to be complete after round 3. One hundred ninety phage from the third round of each selection were individually tested by ELISA on the protein against which they were selected and simultaneously on bovine serum albumin (BSA)-blocked plastic (data not shown). Approximately 50% of the phage tested could be characterized as "strong positives" (i.e., they gave A 405 readings >1.0, with >15-fold higher signal on target protein over assay background). Another 25% were plastic or BSA binders, and the remainder bound target weakly or not at all. As an additional control for nonspecific binding, 24 of the best binders were also tested on immobilized cyclophilin A, to which no detectable binding occurred.
Specificity testing on cell lines
A total of 94 phage that were strongly positive in the EGFR protein ELISA were then tested in a cell-based ELISA. In this assay, all the phage were simultaneously tested for binding to mouse NR6 fibroblasts expressing human EGFR (NR6W) or human EGFRvIII (NR6M) and the parental cell line expressing no endogenous EGFR (NR6V) 28 . The results are shown in Figure 1 and can be summarized as follows: (1) 39% of the tested phage could be characterized as "strong positives" (A 405 >1.0 on EGFR-expressing cells, >0.5 on EGFRvIII-expressing cells); (2) most of the phage selected on either type of receptor bind to cells expressing either type of receptor, but only 1 phage binds (weakly) to the parental cells and/or to plastic; and (3) 2 phage clones (in wells C1 and G1) appear to be specific for wild-type but not vIII mutant EGFR-expressing cells. Following this experiment, several hundred additional phage were assayed by cell ELISA, and EGFR-specific phage were readily identified.
Competition ELISA showing cross-specificity with EGFR-specific mAbs
To determine whether the VHH-phage have cross-specificity with EGFR-specific mAbs, we performed phage versus mAb competition experiments on fixed glioblastoma cells expressing EGFR. All the anti-EGFR mAbs are specific for the ECD. A wild-type EGFR-specific phage (from well C1 in Fig. 1) was competed by 2 different anti-EGFR mAbs, F2A2 and H11, but not by anti-EGFR mAbs B10D11 (Fig. 2) and D2C7 (data not shown), an anti-EGFRvIII-specific mAb or an antiactin mAb. The 2 competing antibodies, F2A2 and H11, have cross-specificity with each other (data not shown), and the data suggest that this VHH-phage shares the same specificity with them. Conversely, 9 other VHH-phage are competed by B10D11 and D2C7 but not by F2A2 and H11.
Immunoprecipitation of target with immobilized VHH domains
Free VHH domains containing a polyhistidine tag were expressed in and purified from E. coli strain HB2151 by nickel affinity chromatography. VHH domains 101, 102, 104, 110, 122, and 139 and 1 random VHH clone (RP2) were bound in individual wells of a nickel-chelate microplate; an eighth well received only buffer. NR6W lysate was added to each well and allowed to incubate for 16 h at 4°C. The lysate was removed, the wells were washed, and remaining protein was eluted. Samples were subjected to SDS-PAGE, and proteins were transferred to a PVDF membrane that was then probed for EGFR. An EGFR-positive band was obtained with almost all of the VHH domains of interest, and no band was seen with the negative controls (Fig. 3A) . VHH122, for reasons we do not understand, does not pull down EGFR in the format of this assay. However, as described below, EGFR (visible by Coomassie Blue staining and identity confirmed by peptide sequencing) could be isolated from cell lysates incubated with VHH122 covalently linked to Sepharose beads. In addition, real-time association and dissociation of VHH122 with immobilized EGFR ECD could be measured in surface plasmon resonance experiments (see below).
Identification of protein immunoprecipitated by VHH122
VHH122 and negative control VHH RP2 were each coupled to CNBr-activated Sepharose 4B beads (GE Healthcare) and incubated with NR6W lysate. The beads were washed and protein eluted with SDS-Protein Sample Buffer at 95°C. Eluted protein was subjected to SDS-PAGE and stained with Coomassie Blue; 2 bands, one of an apparent molecular weight of 170,000 and one of an approximate molecular weight of 17,000, were seen in the VHH122 lane (data not shown). Only the 17,000 molecular weight species (the size of the VHH domain) was seen in the RP2 control lane. The single band unique to the VHH122 lane was excised from the gel. This protein was subjected to tryptic digestion, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) peptide fingerprint analysis, and tandem mass spectrometry (MS/MS) sequencing. The analysis identified the immunoprecipitated protein as EGFR (Fig. 3B) .
Specificity of VHH122 for EGFR-expressing cells by flow cytometry
NR6W and NR6V cells (8 × 10 5 ) were mixed with either VHH122 or the random control RP2 at 15 µg/mL and incubated for 1 h on ice. The cells were washed and stained with FITC-conjugated mouse anti-His tag mAb and washed and analyzed in a Becton Dickinson FACScalibur flow cytometer. The results of the flow cytometry experiment are shown in Figure 4 , where the single shifted peak represents VHH122 bound to NR6W cells. 
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Sequences, isoelectric points, and stability of EGFR-specific VHH domains
The DNA sequences of VHH domains in the phage with highest apparent affinity by cell ELISA were determined. A total of 167 sequences were obtained, 47 of which were unique. All 47 of these sequences were aligned using the Clustal W function of Vector NTI (Invitrogen), and a guide tree of sequence relatedness was constructed using the method of Saitou and Nei. 36 The guide tree and alignment of a representative subset of 15 sequences are shown in Figure 5A,B . The EGFR-specific VHH domains fall into 2 groups. Group 1 (33 VHH domains) is highly conserved overall and contains the consensus motifs GSTVS(G/D)NTMG in CDR1, ISSVGVT in CDR2, and NALGTGR(G/A)N in CDR3. (CDR/FR boundaries are demarcated per Harmsen et al. 37 ) None of these motifs was seen in 20 randomly chosen phage from the 10 7 member library before selection. Group 2 (13 VHH domains) displays more heterogeneity throughout the molecule, particularly in CDR3, where length of this subdomain varies between 5 and 19 amino acids. Overall, the sequence identity between any 2 clones varies between 67% and 99%. The predicted protein molecular weights ranged from 16 to 18 kDa, and calculated isoelectric points ranged from 5.31 to 9.01. To examine VHH domain stability in serum, we added purified VHH122 protein at a final concentration of 10 µg/mL to either mouse serum (Invitrogen) or normal human serum (from our repository). As measured by Western blot, VHH122 appeared to be stable to serum proteases over the course of 8 h at 37°C (data not shown). In addition, VHH122 retains full EGFR binding activity (as measured in an ELISA with immobilized EGFR ECD) after a 1-h incubation at temperatures ranging from 4°C to 65°C but loses all activity upon boiling and cooling to room temperature (data not shown).
Binding kinetics and thermodynamics
The ka, kd, and KD values were determined for the binding of 2 VHH domains to the ECDs of EGFR and EGFRvIII by surface plasmon resonance (SPR). The ECDs were coupled to Biacore CM5 chips, and VHH domains were sequentially flowed over each protein in the Biacore 3000. VHH122 and VHH205 both produced well-defined sensograms from which kinetic and rate constants could be derived; these are shown in Table 1 . VHH122 bound to both EGFR and EGFRvIII with roughly equal affinity, approximately 40 nM. Two other VHH domains dissociated rapidly, such that their sensograms could not be fit by the instrument software. The random VHH domain RP2 was also tested and did not bind to either target.
DISCUSSION
Monoclonal antibodies are useful but not optimal tumortargeting agents because high interstitial pressure inside tumors prevents convection of antibodies from blood vessels, and the large size of an IgG (160 kDa) limits its rate of diffusion. 38 In addition, mAbs are slowly cleared from the blood with the potential to cause damage to normal tissue, and some can be immunogenic. A smaller, nonimmunogenic targeting agent with fast tumor infiltration kinetics that retained the high specificity and affinity of an antibody would be of tremendous utility in tumor imaging and therapy. VHH domains of camels and llamas are one tenth the molecular weight of a conventional antibody yet exhibit equivalent specificity. They are thermodynamically stable, 39 are stable in serum, and appear to be nonimmunogenic in humans. By these criteria, VHH domains demonstrate the potential to be ideal tumor-targeting agents.
To create a resource for the isolation of tumor-specific targeting agents, we immunized a llama with 2 different types of tumor cell lysates, purified wild-type and vIII mutant EGFR ECDs, and constructed a VHH domain phage library. After 3 rounds of selection on each type of EGFR ECD and assay by ELISA on protein, half of all VHH-phage tested were EGFR specific, validating the approach with respect to this target. Two clones bound only to wild-type EGFR and not the mutant, but none of the clones was EGFRvIII specific. Thus, it appears that most of the phage may be directed toward epitopes that are common to wild-type and vIII mutant EGFR. This is not surprising because the epitope defined by the vIII mutation is small compared with the size of the protein. 17 Perhaps selection on a peptide spanning the EGFRvIII mutation would yield EGFRvIII-specific VHH domain phage.
DNA sequencing and Clustal W analysis of 47 translated coding regions revealed a family of VHH domains that could be split into 2 major branches because of amino acid sequence similarities in their CDRs. Nine of the phage, some of which were placed in the first branch and some in the second, were competed by the antibodies D2C7 and B10D11 but not by F2A2 and H11, and 1 phage (wild-type EGFR specific) showed the converse behavior. This result implies that 2 binding sites on EGFR are targeted by phage in the library. The fact that the VHH-phage compete with mAbs for binding to the cellular receptor implies that the VHH domains may be recognizing some of the same epitopes as the mAbs. The binding sites for mAbs and VHH domains could also be overlapping or separate but allosteric. The observed sequence variation and wide range of isoelectric points (pI values between 5.3 and 9.3) portend different degrees of physical and/or biological stability between the VHH domains, which might be exploited in development of therapeutic or imaging agents. We demonstrated that the VHH domains can bind to cells as free antibodies and used them to pull out the receptor by immunoprecipitation from cell extracts. MALDI-TOF peptide fingerprint analysis and MS/MS sequencing offered direct proof of the identity of the target. To our knowledge, this is the first direct confirmation of the identity of an integral cell membrane receptor target of a phage-displayed antibody. We suggest that the methods presented here can be used to identify the targets of potentially useful VHH domains isolated from the library in the future.
The VHH domain technology is versatile, and several studies have focused on the pharmacokinetics and possible therapeutic value of these molecules in vivo. Cortez-Retamozo et al. 25 carried out biodistribution studies with 3 125 I-labeled lysozyme-specific VHH domains and studied targeting to tumor xenografts expressing surface lysozyme. The elimination half-life of these molecules in the blood was 1.5 h, and label accumulated in tumors in the range of 2% ID/g tumor after 2 h. Roovers et al. 27 described several EGFR-specific VHH domains derived from a llama immunized with EGFRpositive A431 cells. A multivalent construct was shown to have an in vivo half-life of 1 h in contrast to a divalent construct with a half-life of 44 h, showing that the half-life of these molecules is tunable. The VHH domains acted as antagonists, blocking EGF-induced tyrosine phosphorylation and EGF-induced cell proliferation, and in a mouse xenograft model, they delayed the outgrowth of A431 solid tumors. VHH domains have also been assessed as imaging agents after 99m Tc labeling followed by single photon emission computed tomography (SPECT) imaging of carcinoembryonic antigen (CEA)-expressing 40 and EGFR-expressing tumors 41, 42 in mice. The VHH domains in these studies were able to distinguish tumors expressing high and low (or no) target receptor, although blood half-lives were variable, and much remains to be learned about the factors affecting processing and secretion of these molecules in vivo. However, these studies demonstrate the great potential for VHH domains in cancer imaging and therapy. We expect our llama phage display library to provide a ready source of these probes for EGFR and other tumor cell targets. Independent measurements made on different days are given. EGFR, epidermal growth factor receptor.
